Verve Therapeutics Inc (NASDAQ: VERV) is -3.01% lower on its value in year-to-date trading and has touched a low of $2.86 and a high of $9.31 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VERV stock was last observed hovering at around $5.25 in the last trading session, with the day’s gains setting it 0.22%.
Currently trading at $5.47, the stock is 27.65% and -4.14% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.57 million and changing 4.19% at the moment leaves the stock -7.25% off its SMA200. VERV registered -17.62% loss for a year compared to 6-month gain of -3.19%. The firm has a 50-day simple moving average (SMA 50) of $5.7567 and a 200-day simple moving average (SMA200) of $5.89625.
The stock witnessed a -5.36% loss in the last 1 month and extending the period to 3 months gives it a -29.87%, and is 10.06% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.29% over the week and 13.40% over the month.
Verve Therapeutics Inc (VERV) has around 274 employees, a market worth around $466.18M and $32.33M in sales. Profit margin for the company is -614.59%. Distance from 52-week low is 90.94% and -41.21% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.94%).
with sales reaching $9.38M over the same period.The EPS is expected to shrink by -12.64% this year, but quarterly earnings will post -25.21% year-over-year. Quarterly sales are estimated to grow 64.63% in year-over-year returns.
256.0 institutions hold shares in Verve Therapeutics Inc (VERV), with institutional investors hold 95.05% of the company’s shares. The shares outstanding are 88.76M, and float is at 66.12M with Short Float at 25.15%. Institutions hold 90.26% of the Float.
The top institutional shareholder in the company is ALPHABET INC. with over 12.35 million shares valued at $60.26 million. The investor’s holdings represent 14.6618 of the VERV Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.62 million shares valued at $32.31 million to account for 7.8598 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 5.26 million shares representing 6.2492 and valued at over $25.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 5.3768 of the shares totaling 4.53 million with a market value of $22.1 million.
Verve Therapeutics Inc (VERV) Insider Activity
The most recent transaction is an insider sale by Kathiresan Sekar, the company’s Chief Executive Officer. SEC filings show that Kathiresan Sekar sold 9,822 shares of the company’s common stock on Apr 02 ’25 at a price of $4.15 per share for a total of $40761.0. Following the sale, the insider now owns 0.35 million shares.
Verve Therapeutics Inc disclosed in a document filed with the SEC on Apr 02 ’25 that Nickerson Joan (Chief Administrative Officer) sold a total of 2,777 shares of the company’s common stock. The trade occurred on Apr 02 ’25 and was made at $4.15 per share for $11525.0. Following the transaction, the insider now directly holds 17420.0 shares of the VERV stock.
Still, SEC filings show that on Apr 02 ’25, Ashe Andrew D. disposed off 2,681 shares at an average price of $4.15 for $11126.0. The insider now directly holds 348,828 shares of Verve Therapeutics Inc (VERV).
